Comparison of Long-Term Clinical Outcomes after the Second-Generation Cobalt–chromium Sirolimus-Eluting Stents Implantation in Diabetic Versus Non-Diabetic Patients: a Subgroup Analysis from the Prospective FOCUS Registry

J. Yang,F. Zhang,J. Qian,L. Ge,J. Zhou,J. Ge

DOI: https://doi.org/10.3109/07853890.2016.1162324

2016-01-01

Abstract:Background: Diabetes mellitus (DM) was broadly acknowledged as a risk factor for adverse events after coronary stent implantation. However, the role of DM in patients treated with second-generation cobalt-chromium sirolimus-eluting stents (CoCr-SES) was less known. Methods: A total of 4720 patients available for 3-year follow-up in the prospective FOCUS registry were subdivided into the DM group and the non-DM group to assess the effect of DM on the clinical outcomes after CoCr-SES implantation both before and after propensity score matching. Results: The rates of major adverse cardiovascular event was low (<10%) in both DM and non-DM groups but significantly greater in the DM group after matching (9.6% versus 6.1%; p=0.005). Although the soft endpoints including target vessel revascularization (2.3% versus 2.3%; p=0.938) and target lesion revascularization (1.2% versus 1.1%; p=0.828) was not significantly different between two groups, the hard endpoints represented by cardiovascular death or myocardial infarction (7.3% versus 5.3%; p=0.012) demonstrated a significant increase in the DM group. Conclusions: This subgroup analysis demonstrated that DM significantly increased the risk of adverse events after implantation of CoCr-SES, but the general safety and efficacy performance of CoCr-SES in both diabetic and non-diabetic patients was satisfying and comparable with other types of new-generation drug-eluting stents.